Trial
NCT02119663
A Study of Ruxolitinib in Pancreatic Cancer Patients
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Incyte Corporation
Collaborators
—
Condition
Pancreatic Cancer
Intervention
Ruxolitinib
Why stopped
The safety committee found no safety issues but recommended halting the study based on a lack of efficacy in a similar trial. The sponsor terminated the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-02-13